Hot Search:

C57BL/6JGpt-H11em1Cin(K18-hACE2)/Gpt

H11-K18-hACE2|Strain NO.T037657

Knockin (KI)

  • Product Type:
  • Quantity: - +
  • Sex:
  • Age:
  • Genotype:
BASIC INFORMATION
Strain Name: C57BL/6JGpt-H11em1Cin(K18-hACE2)/Gpt
Strain Number: T037657
Official Symbol: ACE2,H11
Strain Strategy: T037657.H11-K18-hACE2 strain info.pdf
Official Full Name: angiotensin I converting enzyme 2
Also Known As: ACEH,hACE2
NCBI Number: 59272
Chromosome: 11
Research Areas: Humanized model,Gene humanization model
Strain Background: [N000013] C57BL/6JGpt
Modification Type: Knockin (KI)
Inventory Status: Live,Cryopreserved
Sale Status: IF (Available for Distribution)
Health Status: Specific pathogen free (SPF)
Health Report: Please log in to view
Publications: 1. Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2. Antiviral Res (2023)2. Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice. Virol Sin (2022)3. SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal transduction and targeted therapy (2021)4. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics. Nature Communications (2021)5. Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduction and Targeted Therapy (2021)6. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell research (2021)7. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. Journal of hematology & oncology (2020)8. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. EBioMedicine (2022)9. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Antiviral Research (2022)10. NSUN2-mediated M(5)c methylation of IRF3 mRNA negatively regulates type I interferon responses during various viral infections. Emerging Microbes & Infections (2023)11. Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)12. Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates. SCI ADV (2023)13. Soluble CD4 effectively prevents excessive TLR activation of resident macrophages in the onset of sepsis. Signal Transduct Target Ther (2023)14. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge. Signal Transduct Target Ther (2023)15. A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir. Signal Transduct Target Ther (2023)16. Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines. Vaccines (2023)17. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat Commun (2023)18. Intranasal mask for protecting the respiratory tract against viral aerosols. Nat Commun (2023)19. Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants. J Virol (2023)20. Preclinical evaluation of the SARS-CoV-2 M(pro) inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat Microbiol (2024)21. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. NPJ Vaccines (2024)22. An optimized high-throughput SARS-CoV-2 dual reporter trans-complementation system for antiviral screening in vitro and in vivo. Virol Sin (2024)23. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice. J Exp Clin Cancer Res (2024)24. Helminth alleviates COVID-19-related cytokine storm in an IL-9-dependent way. AMERICAN SOCIETY FOR MICROBIOLOGY (2024)25. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development. Emerg Microbes Infect (2024)26. Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1. Cell Rep (2024)27. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug. Cell Death Dis (2024)28. Sanhan Huashi Formula and Its Bioactive Compounds Exert Antiviral and Anti-Inflammatory Effects on COVID-19. Engineering (2024)29. Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2. Front Immunol (2024)30. A decavalent composite mRNA vaccine against both influenza and COVID-19. mBio (2024)31. Cdc42 improve SARS-CoV-2 spike protein-induced cellular senescence through activating of Wnt/β-Catenin signaling pathway. Front Cell Infect Microbiol (2024)32. A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity. EBioMedicine (2024)33. Nonenzymatic lysine d-lactylation induced by glyoxalase II substrate SLG dampens inflammatory immune responses. Cell research (2025)34. Humanized Major Histocompatibility Complex Transgenic Mouse Model Can Play a Potent Role in SARS-CoV-2 Human Leukocyte Antigen-Restricted T Cell Epitope Screening. Vaccines (Basel) (2025)35. Design, optimization, and evaluation of lyophilized lipid nanoparticles for mRNA-based pulmonary mucosal vaccination. Mater Today Bio (2025)